Genomic Health, Inc. (GHDX.W)
17.47USD
4 Feb 2010
$0.24 (+1.42%)
$17.47
--
$17.32
$16.80
105,426
242,274
$27.22
$15.81
GHDX.W
About
Overall
| Beta: | 0.72 |
| Market Cap (Mil.): | $491.53 |
| Shares Outstanding (Mil.): | 28.61 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| GHDX.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 42.00 | -- | -- |
| ROI: | -13.57 | 1.25 | 2.30 |
| ROE: | -13.97 | 2.09 | 2.82 |
Gene discovery may help guide breast cancer care
* Abnormality in 2 genes makes chemotherapy less effective
Chemotherapy boosts breast cancer survival -study
CHICAGO, Dec 10 (Reuters) - Chemotherapy helps improve breast cancer survival in post-menopausal women, adding to a long-standing debate about how best to treat these women, U.S. researchers said on Thursday.
Risks to personalized medicine seen in U.S. reform
CHICAGO (Reuters) - The federal government's push to control health costs through comparative effectiveness research could threaten strides in personalized medicine, in which medicines are tailored to an individual's genetic makeup, the chief of the National Institutes of Health said on Monday.
Risks to personalized medicine seen in U.S. reform
* Says comparative studies need to include genetic data
Gene test predicts risk of colon cancer return
LOS ANGELES, May 14 (Reuters) - A genetic test that predicts whether colon cancer will return in certain patients will have a significant impact on treatment options, researchers said on Thursday.
HEADLINE STOCKS-U.S. stocks on the move on April 15
(Updates to afternoon trade, adds Charles Schwab, Procter & Gamble, AMR Corp and Infinity Pharmaceuticals)
HEADLINE STOCKS-U.S. stocks on the move on April 15
(Updates to after the open, adds Burger King, Starbucks, UBS, Peabody Energy and Piper Jaffray)
HEADLINE STOCKS-U.S. stocks to watch on April 15
NEW YORK, April 15 (Reuters) - Some U.S. stocks to watch on Wednesday:
UPDATE 1-Genomic Health colon cancer test meets main trial goal
April 14 (Reuters) - Molecular diagnostics company Genomic Health Inc said a validation study of a test that predicts the possibilities of recurrence of stage II colon cancer met the main trial goal.
UPDATE 1-Genomic posts narrower Q4 loss; sees loss for 2009
Feb 3 (Reuters) - Genomic Health Inc posted a narrower-than-expected quarterly loss, helped by a 60 percent jump in sales of its breast cancer test.
Competitors
| Price | Change | |
|---|---|---|
| Celera Corporation (CRA.OQ) | $6.58 | +0.36 |
| Clarient, Inc. (CLRT.OQ) | $2.16 | -0.02 |
| Genzyme Corporation (GENZ.OQ) | $54.87 | +0.38 |
| Quest Diagnostics Incorporated (DGX.N) | $55.68 | +0.68 |
| Laboratory Corp. of America Holdings (LH.N) | $70.15 | +0.01 |
| Bayer AG (BAYGn.DE) | €48.83 | +0.99 |
| Bayer AG (BAYE.F) | -- | -- |
| Siemens AG (SIEGn.DE) | €63.83 | +0.85 |
| Roche Holding Ltd. (ROG.VX) | CHF175.50 | -0.60 |
| Johnson & Johnson (JNJ.N) | $62.76 | +0.39 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
